已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial

医学 打开标签 临床试验 皮肤病科 内科学
作者
Jinhui Shu,Wei Xie,Chunli Mei,Anqi Ren,Sha Ke,Mei-Lin Ma,Zisong Zhou,Yu Hu,Heng Mei
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:83: 103229-103229 被引量:38
标识
DOI:10.1016/j.eclinm.2025.103229
摘要

Background: Systemic lupus erythematosus (SLE) is a classic systemic autoimmune disease mediated by autoantibodies. Chimeric antigen receptor T (CAR-T) cell therapy, known for its success in cancer, has shown promise in achieving durable B cell depletion and long-term remission in SLE. Relmacabtagene autoleucel (relma-cel) is the second anti-CD19 CAR-T product approved for marketing by the National Medical Products Administration (NMPA) in China and demonstrates its long-term efficacy in relapsed/refractory (r/r) large B cell lymphoma (LBCL). We report the results from a phase I open-label clinical trial of relma-cel in treating patients with moderately to severely active SLE. Methods: anti-CD19 CAR-T cells. All patients received lymphodepletion chemotherapy with fludarabine and cyclophosphamide. The primary endpoints were the incidence of dose-limiting toxicities (DLTs) and adverse events (AEs). Secondary endpoints included the evaluation of standard cellular pharmacokinetic parameters, the SLE Responder Index (SRI) response rate, and changes from baseline in the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI), British Isles Lupus Assessment Group 2004 (BILAG-2004) and Physician's Global Assessment (PGA) scores post-treatment. This trial is registered with ClinicalTrials.gov, NCT05765006. Findings: was 18.74 CD3+CAR+ cells/μL (range: 7.94-228.36) by flow cytometry and 81766.5 copies/μg DNA (range: 50,979-1,140,893) by quantitative real-time PCR (qPCR). In all patients treated with relma-cel, CD19+ B cells in peripheral blood were almost completely depleted within 11-15 days and gradually recovered within 2-6 months. All patients achieved SRI response. Four patients achieved Definition of Remission in SLE (DORIS) remission criteria and seven patients reached the Lupus Low Disease Activity State (LLDAS) criteria within 1-4 months following relma-cel infusion. Interpretation: This study preliminarily demonstrated that relma-cel is an effective and safe CAR-T product for the treatment of patients with moderately to severely active SLE, providing valuable clinical insights into the management of rare complications. Further studies with larger sample sizes are warranted. Funding: National Natural Science Foundation of China.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美世界的应助被包容耳机采纳,获得30
刚刚
刚刚
xiaoyangjuejue完成签到,获得积分10
1秒前
风吹麦浪的应助被星辰大海采纳,获得10
1秒前
简单寒天发布了新的文献求助10
1秒前
edisonzz发布了新的文献求助30
1秒前
randomname完成签到,获得积分10
4秒前
4秒前
搜集达人的应助被江就采纳,获得10
5秒前
情怀的应助被隐形的凡阳采纳,获得10
5秒前
5秒前
深情安青的应助被蕾蕾采纳,获得30
6秒前
6秒前
7秒前
7秒前
cz完成签到 ,获得积分10
7秒前
哈哈哈发布了新的文献求助30
9秒前
阳光完成签到,获得积分10
9秒前
CC发布了新的文献求助10
10秒前
10秒前
KTV发布了新的文献求助10
10秒前
Xi完成签到 ,获得积分10
10秒前
JOJO发布了新的文献求助10
11秒前
ZYLLYL完成签到,获得积分10
12秒前
12秒前
CodeCraft的应助被Roy007采纳,获得10
13秒前
111完成签到,获得积分10
13秒前
我是老大的应助被冬雾采纳,获得10
13秒前
14秒前
四旬完成签到,获得积分10
14秒前
外向大楚完成签到,获得积分10
15秒前
16秒前
张三完成签到,获得积分10
16秒前
慕青的应助被Bai采纳,获得10
17秒前
苏景烟发布了新的文献求助20
17秒前
小二郎的应助被szxa采纳,获得10
17秒前
爱科研的小王同学完成签到,获得积分10
18秒前
科研通AI6.4的应助被一期一会采纳,获得10
18秒前
19秒前
charliechen完成签到 ,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179129
求助须知:如何正确求助?哪些是违规求助? 9569710
关于积分的说明 21806324
捐赠科研通 7774507
什么是DOI,文献DOI怎么找? 3433008
关于科研通互助平台的介绍 2556912
邀请新用户注册赠送积分活动 2478649